Targeted binding agents directed to KDR and uses thereof—035
US8119130B2 · kind B2 · utility
12Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2008 |
| Grant date | Feb 21, 2012 |
| Priority date | — |
| Expiry date | Jul 23, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.